Amicus Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bradley L. Campbell
- Full Time Employees
- 499
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3675 Market Street Philadelphia PA United States of America 19104
- IPO Date
- May 31, 2007
- CIK
- 0001178879
- Website
- amicusrx.com
- Similar Companies
- Business
- Amicus Therapeutics, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of novel medicines for rare diseases. Its core products include Galafold, the first oral monotherapy for adults with Fabry disease who have amenable galactosidase alpha gene variants; and Pombiliti combined with Opfolda, a two-component treatment designed for adults with late-onset Pompe disease to improve enzyme uptake in disease-relevant tissues. The company operates globally, with a commercial presence in the United States, Europe, and select other international markets. Founded in 2002 and headquartered in Princeton, New Jersey, Amicus also maintains a collaboration with GlaxoSmithKline for the development and commercialization of Galafold. In recent major developments, Amicus entered a $430 million strategic financing collaboration with Blackstone in 2023, comprising a $400 million senior secured term loan to refinance existing debt and a $30 million equity investment, strengthening its financial position and supporting ongoing operations. The company launched Pombiliti plus Opfolda successfully in key markets including the U.S., Germany, Austria, Spain, and the U.K., with plans to expand launches into up to 10 new countries in 2025, including Australia and anticipated approvals in Canada and Japan. Amicus achieved its first full year of non-GAAP profitability in 2024, driven by robust revenue growth from both Galafold and Pombiliti plus Opfolda, with total revenue reaching $528 million, a 33% increase year-over-year, and projects continued annual revenue growth of 17-24% during 2025. Amicus serves the rare disease segment within biotechnology and pharmaceutical industries, targeting patients with genetic disorders such as Fabry and Pompe diseases. The company continues to pursue clinical and commercial advancements, including intellectual property settlements and expanded patient access globally. It anticipates surpassing $1 billion in total sales by 2028, reflecting strategic expansion and successful commercialization efforts in rare disease therapeutics. The company maintains approximately 499 employees under the leadership of President and CEO Bradley Campbell.
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC
Market Today: Blue Owl payout, GDP miss, oil and EV moves
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
What to Expect From These Drug/Biotech Players This Earnings Season?
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?